ALX Oncology appoints Jason Lettmann as CEO; Jaume Pons becomes CSO

ALX ONCOLOGY HOLDINGS INC

Jason Lettmann named CEO effective Sept 6, 2023; succeeds Jaume Pons who becomes President and CSO.
Lettmann receives $675K base salary, 55% bonus target, and 1,200,000 share stock option grant.
Pons retains $650K base salary, same bonus target, and existing equity awards unchanged.
Lettmann brings biotech CEO (Promedior/Roche) and VC experience; Board member since 2015.
CEO change comes as evorpacept ASPEN-06 Phase 2 data in HER2+ gastric cancer remains on track for Q4'23.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jaume Pons

President and Chief Scientific Officer

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2023-09-06
Successor: Jason Lettmann
Filed: September 6, 2023, 7:59 PM ET

Effective on the same date, Dr. Jaume Pons will no longer be the Company’s Chief Executive Officer and will serve as the Company’s Chief Scientific Officer while continuing to serve as President.

Appointed

Jason Lettmann

Chief Executive Officer

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2023-09-06
Filed: September 6, 2023, 7:59 PM ET

On September 6, 2023, ALX Oncology Holdings Inc. (the “Company”) appointed Jason Lettmann, age 46 and a current member of the Company’s Board of Directors (the “Board”), as the Company’s Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jaume Pons changed role as President and Chief Scientific Officer at ALX ONCOLOGY HOLDINGS INC.

Action: will no longer be CEO and will serve as CSO while continuing as President
Role: President and Chief Scientific Officer

Exact text from the filing

Effective on the same date, Dr. Jaume Pons will no longer be the Company’s Chief Executive Officer and will serve as the Company’s Chief Scientific Officer while continuing to serve as President.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Lettmann was appointed as Chief Executive Officer at ALX ONCOLOGY HOLDINGS INC.

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On September 6, 2023, ALX Oncology Holdings Inc. (the “Company”) appointed Jason Lettmann, age 46 and a current member of the Company’s Board of Directors (the “Board”), as the Company’s Chief Executive Officer.

View on SEC.gov

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0001193125-23-229584

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.